<code id='638CA88C74'></code><style id='638CA88C74'></style>
    • <acronym id='638CA88C74'></acronym>
      <center id='638CA88C74'><center id='638CA88C74'><tfoot id='638CA88C74'></tfoot></center><abbr id='638CA88C74'><dir id='638CA88C74'><tfoot id='638CA88C74'></tfoot><noframes id='638CA88C74'>

    • <optgroup id='638CA88C74'><strike id='638CA88C74'><sup id='638CA88C74'></sup></strike><code id='638CA88C74'></code></optgroup>
        1. <b id='638CA88C74'><label id='638CA88C74'><select id='638CA88C74'><dt id='638CA88C74'><span id='638CA88C74'></span></dt></select></label></b><u id='638CA88C74'></u>
          <i id='638CA88C74'><strike id='638CA88C74'><tt id='638CA88C74'><pre id='638CA88C74'></pre></tt></strike></i>

          leisure time

          leisure time

          author:focus    Page View:4595
          Vertex Pharmaceuticals Inc. building
          Craig F. Walker/The Boston Globe

          Vertex Pharmaceuticals said Friday that, over a year after receiving the company’s stem-cell therapy, two type 1 diabetes patients no longer need to take insulin injections and saw stark reductions in a biological marker of disease. 

          The results, presented at the American Diabetes Association conference in San Diego, bolstered experts’ hopes that the treatment could provide a functional cure for some patients. In 2021, Vertex announced dramatic results from the first man to receive the treatment, but researchers cautioned it was just one person, who had only been followed for 90 days.

          advertisement

          “The data look as good as they could be,” said Jeanne Loring, a stem cell expert and professor emeritus at Scripps Research not involved in the work, in an email.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Activists slam private health insurers over coverage restrictions
          Activists slam private health insurers over coverage restrictions

          ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

          read more
          Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal
          Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

          DarronCummings/APEliLillysaidTuesdaythatitwillpurchaseDICETherapeutics,asmallcompanydevelopinganexpe

          read more
          George Santos makes 1st court appearance after pleading not guilty to 13 counts
          George Santos makes 1st court appearance after pleading not guilty to 13 counts

          1:57GeorgeSantosarrivesatfederalcourtJune30,2023,inCentralIslip,N.Y.JohnMinchillo/APRep.GeorgeSantos

          read more

          Study finds new variant for Parkinson’s in African populations

          AdobeAgroupofNigerian,British,andU.S.doctorshavediscoveredageneticvariantthatincreasestheriskofParki